By Michele Maatouk
Date: Thursday 21 Nov 2024
(Sharecast News) - Peel Hunt initiated coverage on Avacta on Thursday with a 'buy' rating and 99p price target as it pointed out three key aspects of the investment case.
By Josh White
Date: Thursday 20 Jun 2024
(Sharecast News) - Life science company Avacta Group announced the appointment of Shaun Chilton as its non-executive chairman on Thursday, succeeding Eliot Forster, who was stepping down from the board with immediate effect.
By Josh White
Date: Thursday 23 May 2024
(Sharecast News) - Avacta Group announced the successful completion of the first cohort and the start of dosing for three patients in the second cohort of the second arm in its phase one trial of AVA6000, a peptide drug conjugate form of doxorubicin chemotherapy, on Thursday.
Currency | UK Pounds |
Share Price | 46.50p |
Change Today | 2.25p |
% Change | 5.08 % |
52 Week High | 140.00 |
52 Week Low | 39.75 |
Volume | 3,090,174 |
Shares Issued | 369.31m |
Market Cap | £171.73m |
Beta | 1.25 |
RiskGrade | 461 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 0 |
Buy | 1 |
Neutral | 1 |
Sell | 0 |
Strong Sell | 0 |
Total | 2 |
No dividends found |
Time | Volume / Share Price |
16:37 | 100,000 @ 46.61p |
16:35 | 9,401 @ 46.50p |
16:35 | 6,401 @ 46.50p |
16:35 | 2,076 @ 46.50p |
16:35 | 38 @ 46.50p |
CFO | Tony Peter Gardiner |
CEO | Christina Coughlin |
You are here: research